Corvex, Inc. Commitments Disclosure

Note 12 – Commitments and Contingencies

 

Operating Leases

 

As of December 31, 2025, the Company has lease agreements for the Corporate headquarters and laboratory space.

On June 19, 2024, the Company executed the third amendment to the original corporate office and facilities lease. The purpose of the amendment was to extend the lease term of the facilities consisting of (i) 5,798 square feet and (ii) 1,890 rentable square feet within the building located at 6800 Koll Center Parkway, Pleasanton, CA. The extended lease term commences on October 1, 2024 and ends on December 31, 2027 with one option to extend the lease for three years. The monthly base rent will be approximately $20,000, with a rent abatement for the first three months of the lease term.

 

The lease amendment was accounted for as a lease modification. The right-of-use asset and operating lease liability for the existing premises were remeasured at the modification date, which resulted in an increase of $0.5 million to both the right-of-use asset and operating lease liabilities.

 

Finance Lease

 

On November 22, 2023, the Company executed a lease agreement for equipment. The lease term is 36 months, and the monthly payment is approximately $1,700. The lease agreement has a bargain purchase option at the end of the lease term.

 

The balances of the lease related accounts as of December 31, 2025 and 2024 are as follows (in thousands):

 

		As of December 31,
Operating and Finance leases		2025				2024
Right-of-use assets		$	415			$	600
Operating lease liabilities - Short-term		$	235			$	169
Operating lease liabilities - Long-term		$	267			$	502
Finance lease liabilities - Short-term		$	18			$	17
Finance lease liabilities - Long-term		$	—			$	18

 

Right-of-use assets are included in other assets on the consolidated balance sheets. The short-term lease liabilities and the long-term lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, on the consolidated balance sheets.

 

The components of lease expense and supplemental cash flow information as of and for the years ended December 31, 2025 and 2024 are as follows (in thousands):

 

		Year Ended December 31,
		2025				2024
Lease Cost:
Operating lease cost		$	257			$	238
Other Information:
Cash paid for amounts included in the measurement of lease liabilities for the year ended		$	285			$	268
Weighted average remaining lease term - operating leases (in years)			2.00				3.00
Average discount rate - operating leases			10.00	%			10.00	%
Weighted average remaining lease term - financing leases (in years)			0.90				2.10
Average discount rate - financing leases			15.08	%			15.08	%

 

Future minimum lease payments are as follows as of December 31, 2025 (in thousands):

 

2026		$	290
2027			280
Total lease payments			570
Less: Interest			(50	)
Total lease liabilities		$	520

Litigation

 

From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company’s business, financial position, results of operations or cash flows.

 

Following a final order issued by the Trademark Trial and Appeal Board (“TTAB”) of the United States Patent and Trademark Office sustaining the opposition of Allora Health, Inc. d/b/a EVVY (“EVVY”) to the Company’s registration of its EVIE mark for two of the three classes of products challenged, and the Company’s subsequent receipt of a cease and desist letter from EVVY relating to its use of the EVIE mark, the Company has paused all commercial sales of its Wellness Ring product marketed under the EVIE name.

 

As a result of these developments, the Company recorded a write-down of inventory related to the Wellness Ring to its estimated net realizable value during the period. The amount of the write-down was recognized in cost of goods sold in the accompanying financial statements.

 

The Company is currently evaluating its legal and strategic options, including potential rebranding, modification of marketing practices, or pursuing legal remedies. At this time, the Company is unable to determine the likelihood of any additional loss or to reasonably estimate the amount or range of potential additional loss, if any, associated with this matter. Accordingly, no additional accrual for loss has been recorded beyond the inventory write-down.

 

The Company will continue to monitor developments related to this matter and will record an additional liability if and when it is determined that a loss is both probable and reasonably estimable in accordance with ASC 450, Contingencies. There can be no assurance that this matter will not have a material adverse effect on the Company’s business, financial condition, or results of operations in future periods (See Note 16).

 

Indemnification

 

The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.

 

The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.

 

No amounts associated with such indemnifications have been recorded as of December 31, 2025.

 

Non-cancelable Obligations

 

One of the Company’s contract manufacturers purchased raw materials for the benefit of the Company of $0.3 million at December 31, 2025 for which title to such materials had not transferred to the Company. The Company did not have any other non-cancelable contractual commitments as of December 31, 2025.

 

Royalty Commitments

 

The Company is required to make certain usage-based royalty payments to a vendor. The royalty amount is calculated based on the number of Wellness Rings shipped, as adjusted for returns and refunds to customers, and the number of specified algorithms developed by the vendor that are included on the Wellness Rings. The maximum amount of the royalty commitment is approximately $6.1 million, and the amount of the research and development expenses paid to the vendor will reduce the total royalty commitment amount. Through December 31, 2025, the Company has paid research and development expenses of approximately $0.9 million to the vendor. The amount of the royalty calculation for the years ended December 31, 2025 and 2024 was not significant.